Phathom Completes Enrollment Ahead of Schedule in Landmark Phase 2 Trial of Vonoprazan for Eosinophilic Esophagitis
Key Insights
Phathom Pharmaceuticals completed enrollment of 95 patients across 41 U.S. sites in its Phase 2 pHalcon-EoE-201 study of VOQUEZNA (vonoprazan) for eosinophilic esophagitis (search), with topline results expected in Q4 2026.
The trial is described as the first large, placebo-controlled clinical study of an acid suppression treatment in EoE, a disease where PPIs are used first-line but none carry FDA approval for this indication.
Vonoprazan, a potassium-competitive acid blocker (PCAB), offers more rapid and sustained acid suppression than conventional PPIs and is already approved for erosive GERD (search) and H. pylori infection.
On June 23, 2026, Phathom Pharmaceuticals announced it had completed patient enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 study, randomizing 95 adults with endoscopically confirmed eosinophilic esophagitis (search) (EoE) and dysphagia across 41 U.S. sites. The trial evaluates VOQUEZNA (vonoprazan) 20 mg once daily versus placebo, with topline results anticipated in the fourth quarter of 2026.
The enrollment completion represents more than a logistical milestone. It signals that Phathom has successfully navigated the operational challenges of identifying and recruiting patients with a disease that affects approximately 1 in 700 Americans yet remains plagued by delayed diagnosis. EoE symptoms — dysphagia, food impaction, chest pain — frequently overlap with GERD and are often dismissed until endoscopy is performed, making trial-eligible patient identification a persistent hurdle for sponsors.
A Regulatory Gap Decades in the Making
Proton pump inhibitors (PPIs) are recommended by the American College of Gastroenterology as first-line therapy for EoE, yet not a single PPI carries FDA approval for this indication. This disconnect between clinical practice and labeling reality forms the backdrop against which Phathom designed pHalcon-EoE-201. The company's press release describes the study as "the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE" — a striking characterization given that PPIs have been the standard of care for years.
The trial's design reflects the regulatory vacuum. Part 1 randomizes patients 1:1 to vonoprazan 20 mg or placebo for 12 weeks, with all completers eligible to enter a 12-week open-label extension in Part 2. There are no adaptive rules, biomarker stratification layers, or interim futility analyses — a streamlined protocol that community gastroenterology practices can execute without dedicated subspecialty research infrastructure.
The PCAB Advantage
Vonoprazan belongs to a novel class of acid-suppressing agents called potassium-competitive acid blockers (PCABs). Unlike conventional PPIs, which require an acidic environment to activate and can lose efficacy during nighttime acid breakthrough, PCABs provide more rapid and sustained acid suppression. VOQUEZNA received FDA approval on November 1, 2023, for erosive GERD (search) — marking the first major innovation in the U.S. erosive GERD market in over 30 years — and is also approved for H. pylori eradication and relief of heartburn associated with non-erosive GERD.
The pharmacological profile of vonoprazan is particularly relevant in EoE because the esophageal inflammatory cascade is at least partially pH-dependent. Whether a more potent acid blocker produces a meaningfully better histologic outcome than a conventional PPI would have produced remains an open question — one that pHalcon-EoE-201 cannot directly answer because it compares vonoprazan only to placebo, with no approved PPI comparator arm.
The Competitive Landscape
The EoE treatment field has evolved since the trial was designed. Sanofi and Regeneron's Dupixent (dupilumab) received FDA approval on January 25, 2024, for EoE in pediatric patients aged 1 to 11 years, cementing its position as the category-defining biologic in the disease. Dupixent already holds adult EoE labeling. A PCAB is unlikely to displace a proven IL-4/IL-13 pathway inhibitor in patients with moderate-to-severe disease.
However, Phathom is targeting a different population: the EoE patient who presents to a community gastroenterologist, receives an off-label PPI prescription, and tolerates it reasonably well but lacks evidence-backed assurance. With EoE affecting roughly 1 in 700 Americans, that population is substantial enough to support commercial launch, particularly if vonoprazan's label carries efficacy language that off-label PPI use cannot provide.
Financial and Regulatory Stakes
Phathom projects net revenues of $320 million to $345 million for full-year 2026 from its existing GERD franchise, with a gross margin of approximately 80%. A labeled EoE indication would extend both the addressable market and the regulatory exclusivity runway. The company's press release explicitly flags pediatric evaluation as the next development step if Phase 2 succeeds — a move that could trigger FDA pediatric exclusivity, granting six additional months of market exclusivity. For a product with an 80% gross margin, that extension represents a material revenue event.
Operational Considerations for Phase 3
The 95-patient, 41-site footprint — averaging roughly 2.3 patients per site — enabled ahead-of-schedule enrollment but may present challenges for a pivotal program. A Phase 3 EoE trial will require deeper site penetration, longer treatment windows, and a primary endpoint likely combining eosinophil count per high-power field with a validated dysphagia symptom score, demanding more rigorous biopsy handling than a Phase 2 protocol typically enforces. The site teams that enrolled one or two patients in pHalcon-EoE-201 will need active re-engagement and retraining before they can anchor a registrational trial.
If vonoprazan clears Phase 2 with a compelling histologic and symptomatic response profile, Phathom will be negotiating the regulatory pathway for a labeled acid suppression indication in EoE from scratch — without precedent to cite, but with the potential to generate the first placebo-controlled efficacy signal for an entire drug class in this underserved indication.